Arvinas Inc

Arvinas Inc. is a clinical-stage biopharmaceutical company headquartered in New Haven, Connecticut. The company employs 394 people and has generated $100 million in revenue. Arvinas focuses on developing therapies that target and degrade disease-causing proteins. They utilize their proprietary PROTAC® Discovery Engine platform to engineer PROTAC® targeted protein degraders. These therapies aim to leverage the body's natural protein disposal system for selective and efficient removal of harmful proteins. Arvinas has a pipeline of preclinical PROTAC protein degraders targeting both established and previously "undruggable" targets. The company currently has four investigational clinical-stage programs. These programs focus on treating locally advanced or metastatic ER+/HER2- breast cancer with vepdegestrant (ARV-471), metastatic castration-resistant prostate cancer with ARV-766 and bavdegalutamide, and neurodegenerative disorders with ARV-102. For more information, visit www.arvinas.com.